Chitosan-decorated selenium nanoparticles as protein carriers to improve the in vivo half-life of the peptide therapeutic BAY 55-9837 for type 2 diabetes mellitus

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 4819-4828

  Rao, Lei ^a   Ma, Yi ^a   Zhuang, Manjiao ^a   Luo, Tianjie ^a   Wang, Yayu ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

BAY 55 9837; Clearance; Half life; Selenium nanoparticles; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BAY 55 9837; CHITOSAN; SELENIUM NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE; PEPTIDE FRAGMENT; SELENIUM; VASOACTIVE INTESTINAL PEPTIDE (1-7)-GRF (8-27), LYS(15)-ARG(16)-LEU(27)-; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; VALIDATION PROCESS; ZETA POTENTIAL; ANIMAL; CHEMISTRY; HALF LIFE TIME;

ANIMALS; CHITOSAN; DIABETES MELLITUS, TYPE 2; DRUG CARRIERS; DRUG STABILITY; HALF-LIFE; MICE; NANOPARTICLES; PARTICLE SIZE; PEPTIDE FRAGMENTS; SELENIUM; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84930260331     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S67871     Document Type: Article

References (36)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-1053.
2. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001; 414: 821-827.
3. Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol. 2000; 18: 831-833.
4. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010; 28: 917-924.
5. Yung SL, Dela Cruz F, Hamren S, et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem. 2003; 278: 10273-10281.
6. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989; 164: 567-574.
7. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990; 170: 643-638.
8. Winzell MS, Ahrén B. Role of VIP and PACAP in islet function. Peptides. 2007; 28: 1805-1813.
9. Bertrand G, Puech R, Maisonnasse Y, Bockaert J, Loubatières-Mariani M. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol. 1996; 117: 764-770.
10. Borboni P, Porzio O, Pierucci D, et al. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic β-cells and effects of PACAP-38 on components of the insulin secretory system. Endocrinology. 1999; 140: 5530-5537.
11. Tsutsumi M, Claus TH, Liang Y, et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal a potential therapy for type 2 diabetes. Diabetes. 2002; 51: 1453-1460.
12. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993; 214: 829-835.
13. Pan CQ, Li F, Tom I, et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J Pharmacol Exp Ther. 2007; 320: 900-906.
14. Roberts M, Bentley M, Harris J. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002; 54: 459-476.
15. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991; 8: 713-720.
16. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977; 252: 3582-3586.
17. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3: 16-20.
18. Liu W, Li X, Wong YS, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano. 2012; 6: 6578-6591.
19. Makhluf SBD, Abu-Mukh R, Rubinstein S, Breitbart H, Gedanken A. Modified PVA-Fe3O4 nanoparticles as protein carriers into sperm cells. Small. 2008; 4: 1453-1458.
20. Singh Y, Gao D, Gu Z, et al. Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts. Pharm Res. 2012; 29: 2377-2388.
21. Lee C, Choi JS, Kim I, et al. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int J Nanomedicine. 2013; 8: 2975-2983.
22. Rayman MP. The importance of selenium to human health. Lancet. 2000; 356: 233-241.
23. Gao X, Zhang J, Zhang L. Hollow sphere selenium nanoparticles: their in-vitro anti hydroxyl radical effect. Adv Mater. 2002; 14: 290-293.
24. Gates B, Mayers B, Cattle B, Xia Y. Synthesis and characterization of uniform nanowires of trigonal selenium. Adv Funct Mater. 2002; 12: 219-227.
25. Tran PA, Webster TJ. Selenium nanoparticles inhibit Staphylococcus aureus growth. Int J Nanomedicine. 2011; 6: 1553-1558.
26. Li YH, Li XL, Wong YS, et al. The reversal of cisplatin-induced nephrotoxicity by selenium nanoparticles functionalized with 11-mercapto-1-undecanol by inhibition of ROS-mediated apoptosis. Biomaterials. 2011; 32: 9068-9076.
27. Torres SK, Campos VL, León CG, et al. Biosynthesis of selenium nanoparticles by Pantoea agglomerans and their antioxidant activity. J Nanopart Res. 2012; 14: 1-9.
28. Zhang J, Wang H, Yan X, Zhang L. Comparison of short-term toxicity between Nano-Se and selenite in mice. Life Sci. 2005; 76: 1099-1109.
29. Wang H, Zhang J, Yu H. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. Free Radic Biol Med. 2007; 42: 1524-1533.
30. Navarro-Alarcon M, López G, de la Serrana H, Perez-Valero V, López-Martínez C. Serum and urine selenium concentrations as indicators of body status in patients with diabetes mellitus. Sci Total Environ. 1999; 228: 79-85.
31. Kljai K, Runje R. Selenium and glycogen levels in diabetic patients. Biol Trace Elem Res. 2001; 83: 223-229.
32. Zhang SY, Zhang J, Wang HY, Chen HY. Synthesis of selenium nanoparticles in the presence of polysaccharides. Mater Lett. 2004; 58: 2590-2594.
33. Yu B, Zhang Y, Zheng W, Fan C, Chen T. Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles. Inorg Chem. 2012; 51: 8956-8963.
34. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010; 99: 306-314.
35. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004; 1663: 167-177.
36. Imani M, Lahooti-Fard F, Taghizadeh SM, Takrousta M. Effect of adhesive layer thickness and drug loading on estradiol crystallization in a transdermal drug delivery system. AAPS Pharm Sci Tech. 2010; 11: 1268-1275.